0000902664-21-004071.txt : 20210830
0000902664-21-004071.hdr.sgml : 20210830
20210830193923
ACCESSION NUMBER: 0000902664-21-004071
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210826
FILED AS OF DATE: 20210830
DATE AS OF CHANGE: 20210830
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Avoro Capital Advisors LLC
CENTRAL INDEX KEY: 0001633313
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38560
FILM NUMBER: 211225040
BUSINESS ADDRESS:
STREET 1: 110 GREENE STREET
STREET 2: SUITE 800
CITY: NEW YORK
STATE: NY
ZIP: 10012
BUSINESS PHONE: 212-937-4975
MAIL ADDRESS:
STREET 1: 110 GREENE STREET
STREET 2: SUITE 800
CITY: NEW YORK
STATE: NY
ZIP: 10012
FORMER NAME:
FORMER CONFORMED NAME: venBio Select Advisor LLC
DATE OF NAME CHANGE: 20150210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Avoro Ventures LLC
CENTRAL INDEX KEY: 0001879253
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38560
FILM NUMBER: 211225039
BUSINESS ADDRESS:
STREET 1: 110 GREEN STREET, SUITE 800
CITY: NEW YORK
STATE: NY
ZIP: 10012
BUSINESS PHONE: (212) 937-4975
MAIL ADDRESS:
STREET 1: 110 GREEN STREET, SUITE 800
CITY: NEW YORK
STATE: NY
ZIP: 10012
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aghazadeh Behzad
CENTRAL INDEX KEY: 0001701815
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38560
FILM NUMBER: 211225041
MAIL ADDRESS:
STREET 1: C/O AVORO CAPITAL ADVISORS LLC
STREET 2: 110 GREENE STREET, SUITE 800
CITY: NEW YORK
STATE: NY
ZIP: 10012
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aadi Bioscience, Inc.
CENTRAL INDEX KEY: 0001422142
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 611547850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 17383 SUNSET AVENUE
STREET 2: SUITE A250
CITY: PACIFIC PALISADES
STATE: CA
ZIP: 90272
BUSINESS PHONE: 424-473-8055
MAIL ADDRESS:
STREET 1: 17383 SUNSET AVENUE
STREET 2: SUITE A250
CITY: PACIFIC PALISADES
STATE: CA
ZIP: 90272
FORMER COMPANY:
FORMER CONFORMED NAME: Aerpio Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20170316
FORMER COMPANY:
FORMER CONFORMED NAME: ZETA ACQUISITION CORP II
DATE OF NAME CHANGE: 20071227
4
1
ownership.xml
X0306
4
2021-08-26
0
0001422142
Aadi Bioscience, Inc.
AADI
0001701815
Aghazadeh Behzad
C/O AVORO CAPITAL ADVISORS LLC
110 GREENE STREET, SUITE 800
NEW YORK
NY
10012
1
0
1
1
See Remarks
0001633313
Avoro Capital Advisors LLC
110 GREENE STREET
SUITE 800
NEW YORK
NY
10012
1
0
0
1
See Remarks
0001879253
Avoro Ventures LLC
110 GREENE STREET, SUITE 800
NEW YORK
NY
10012
0
0
0
1
See Remarks
Common Stock, $0.0001 par value per share ("Common Stock")
2021-08-26
4
A
0
1911752
13.077
A
2211752
I
See footnotes
Stock option (right to buy)
26.00
2021-08-27
4
A
0
17549
0.00
A
2031-08-27
Common Stock
17549
17549
D
This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.
The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
The securities reported herein were acquired on behalf of accounts managed by Avoro Capital Advisors and Avoro Ventures directly from the Issuer in a PIPE financing completed in connection with the closing of the Agreement and Plan of Merger between the Issuer and Aadi Bioscience, Inc., dated as of May 16, 2021, following which the Issuer changed its name to Aadi Bioscience, Inc.
In connection with the closing of the Merger, as approved by the stockholders of the Issuer on August 17, 2021, the Board granted on August 26, 2021 to the Reporting Person an Initial Award (as defined in the Issuer's Outside Director Compensation Policy and in accordance with the Issuer's 2021 Equity Incentive Plan (the "Plan")). Subject to the Reporting Person continuing to be a Service Provider (as defined in the Plan) through each applicable date, the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month). The grant date is August 27, 2021.
Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer.
Avoro Ventures LLC, by: /s/ Scott Epstein, its Chief Financial Officer & Chief Compliance Officer
2021-08-30
Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Financial Officer
2021-08-30
/s/ Behzad Aghazadeh
2021-08-30